Onconova Therapeutics, Inc. (ONTX) financial statements (2021 and earlier)

Company profile

Business Address 375 PHEASANT RUN
NEWTOWN, PA 18940
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments    212044
Cash and cash equivalents    212044
Restricted cash and investments    00 
Receivables000002 
Prepaid expense0000001
Other current assets0000000
Other undisclosed current assets1923175112
Total current assets:2023185232347
Noncurrent Assets
Property, plant and equipment0000000
Other noncurrent assets0000000
Total noncurrent assets:0000000
TOTAL ASSETS:2024185232347
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10868745
Accounts payable5446534
Accrued liabilities540000 
Employee-related liabilities  21201
Taxes payable      0
Deferred revenue00
Deferred revenue and credits0000
Contract with customer, liability0
Other liabilities    000
Other undisclosed current liabilities  22235
Total current liabilities:10881010810
Noncurrent Liabilities
Liabilities, other than long-term debt34445513
Deferred revenue and credits45513
Deferred revenue34
Contract with customer, liability4
Other liabilities      0
Other undisclosed noncurrent liabilities00023  
Total noncurrent liabilities:44468513
Total liabilities:14121316181324
Stockholders' equity
Stockholders' equity attributable to parent6125(12)41023
Common stock2100000
Additional paid in capital433414387351342328317
Accumulated other comprehensive income (loss)0(0)(0)0(0)(0)(0)
Accumulated deficit(429)(403)(382)(362)(338)(319)(295)
Stockholders' equity attributable to noncontrolling interest   1111
Total stockholders' equity:6125(11)51124
TOTAL LIABILITIES AND EQUITY:2024185232347

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:02116111
Operating expenses(25)(24)(25)(27)(29)(35)(65)
Operating loss:(25)(22)(23)(26)(24)(24)(64)
Nonoperating income (expense)
(Other Nonoperating Income (Expense))
00100(0)(0)
Interest and debt expense      (0)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes(0)0224 0
Loss from continuing operations before income taxes:(25)(21)(21)(24)(20)(24)(64)
Income tax expense (benefit)(0)(0)0(0)(0)(0)(0)
Net loss:(25)(22)(20)(24)(20)(24)(64)
Net income attributable to noncontrolling interest  0  00
Other undisclosed net loss attributable to parent  (0)    
Net loss available to common stockholders, diluted:(25)(22)(21)(24)(20)(24)(64)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(25)(22)(20)(24)(20)(24)(64)
Other comprehensive income (loss)0(0)(0)0(0)(0) 
Other undisclosed comprehensive income      0
Comprehensive loss:(25)(22)(20)(24)(20)(24)(64)
Comprehensive income (loss), net of tax, attributable to noncontrolling interest  (0)  0(0)
Comprehensive loss, net of tax, attributable to parent:(25)(22)(21)(24)(20)(24)(64)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: